Table 1 Sociodemographic and clinical patient characteristics*
From: Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract
| Â | Â | Adjuvant CT n=23 | 1stline pall n=65 | 2ndline pall n=29 | 3rd+ line pall n=8 | p |
|---|---|---|---|---|---|---|
Age | mean (SD) | 66.6 (8.2) | 66.9 (10.0) | 64.5 (10.8) | 60.9 (14.6) | 0.370 |
Sex | men | 34.8% | 52.3% | 65.5% | 50.0% | 0.182 |
| Â | women | 65.2% | 47.7% | 34.5% | 50.0% | Â |
Diagnosis | pancreatic cancer | 78.3% | 72.3% | 75.9% | 87.5% | 0.786 |
| Â | gall cancer | 21.7% | 27.7% | 24.1% | 12.5% | Â |
Time since diagnosis§ | mean (SD) | 3.4 (5.0) | 3.5 (4.5) | 11.1 (7.5) | 24.8 (8.1) | <0.001 |
Metastasis | yes | 17.4% | 48.3% | 62.1% | 87.5% | 0.001 |
| Â | no | 82.6% | 51.7% | 37.9% | 12.5% | Â |
Previous Surgery | yes | 100.0% | 58.9% | 70.4% | 71.4% | 0.004 |
| Â | no | 0.0% | 41.1% | 29.6% | 28.6% | Â |
Chemotherapy regimen | Gemcitabine Mono | 90.9% | 40.6% | 6.9% | 0.0% | <0.001 |
| Â | Gemcitabine Combination Therapy | 9.1% | 45.3% | 27.6% | 25.0% | Â |
| Â | FOLFIRINOX | 0.0% | 4.7% | 0.0% | 0.0% | Â |
| Â | FOLFOX/XELOX | 0.0% | 9.4% | 55.2% | 37.5% | Â |
| Â | FOLFIRI | 0.0% | 0.0% | 3.4% | 12.5% | Â |
| Â | Other | 0.0% | 0.0% | 6.9% | 25.0% | Â |